Guidelines update, v41.2
22 July, 2021
Version 41.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of two new studies on disease-modifying treatments: Canakinumab NEW – one new study comparing canakinumab to placebo in 454 hospitalised patients with severe COVID-19 (Caricchio et al.) Azithromycin – one new study comparing azithromycin to placebo in 263 adult outpatients with COVID-19 (Oldenburg...